Boehringer Ingelheim Continues Commitment to Provide HIV/AIDS Medicines to
Rwanda and Developing World under CAMR and Company Non Assert Declarations
Boehringer Ingelheim has repeatedly stated that patents must not prevent HIV patients from having access to life-saving anti-HIV drugs in resource limited settings. In order to accelerate access to anti-retroviral medicines, the company initiated non-assert declarations in
The non-assert declaration means that the company will not enforce its patent rights against the agreement partner. The company has further waived the provision of a nominal royalty fee under the access policy so the partnering companies can supply the nevirapine containing drugs without any payments to Boehringer Ingelheim. Generic manufacturers whose nevirapine product and production site have been pre-qualified by WHO are enabled to supply in total 78 countries which are either Least Developed Countries (LDC) according to the UNDP classification, or low income countries according to the World Bank classification and all other countries in
By providing only WHO pre-qualified generic producers with the non-assert declaration the quality of nevirapine is guaranteed. This is crucial in countries with weak or non-existent Drug Regulatory Authorities and is in line with our Corporate Responsibility.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim,
For further information: please visit www.boehringer-ingelheim.com
Share this article